Skip to main content

Table 3 Effect of embolic agent on inflammatory markers and hormonal assays

From: Randomised trial of two embolic agents for uterine artery embolisation for fibroids: Gelfoam versus Embospheres (RAGE trial)

 

Embospheres

Gelfoam

Difference between groups (E-G)

Baselinea

6 monthsa

Changeb

p

Baselinea

6 monthsa

Changeb

p

Differencec

p

WCC1

5.9 (2.2)

6.5 (1.8)

0.6 (−0.2 to 1.4)

0.11

6.4 (3.7)

6.3 (1.0)

−0.1 (−2.9 to 2.5)

0.90

0.4 (−0.9 to 1.7)

0.56

CRP2

1.4 (0.8)

2.1 (2.5)

0.9 (−0.7 to 2.5)

0.24

2.8 (2.6)

1.4 (1.0)

−1.3 (−2.6 to 0.1)

0.06

1.5 (−0.4 to 3.5)

0.12

LH3

8.0 (10.1)

11.5 (9.7)

3.5 (−2.6 to 9.6)

0.23

7.5 (9.4)

12.5 (15.9)

5.0 (−0.3 to 10.3)

0.06

−1.5 (−9.2 to 6.2)

0.68

FSH4

11.7 (13.3)

13.9 (12.6)

2.2 (−4.2 to 8.5)

0.46

11.5 (12.6)

21.4 (27.5)

9.9 (−3.2 to 23.0)

0.12

−7.7 (−21.4 to 5.8)

0.25

5E2d

135.5 (107.8308.0)

226.0 (73.3370.8)

d

d

213.0 (80.0,309.3)

129.5 (70.0,315.0)

d

d

d

d

6AMHd

4.0 (4.0,4.6)

4.0 (4.0,4.0)

d

d

4.0 (4.0,4.0)

4.0 (4.0,4.0)

d

d

d

d

  1. aMean (SD)
  2. bMean of change over time calculated as 6 month – baseline, 95% CI of change
  3. cMean difference between embolic agents at 6 months adjusted for baseline values, 95% CI of difference. Positive values indicate higher results in the E group
  4. dMedian (inter-quartile range). No analyses carried out for AMH and E2 due to large numbers of results recorded as `below limit of detection’
  5. 1Normal range for WCC is 4–11 × 109/L. 2Normal CRP is less than 10 mg/L. 3, 4Normal range in pre-menopausal women for LH is 5 to 25 IU/L and FSH is 4.7–21.5 IU/L. 5Normal range for Estradiol (E2) in follicular phase is 77–920 pmol/L, mid cycle is 140–2380 pmol/L and luteal phase is 77–1145 pmol/L. 6Normal range in pre-menopausal women for AMH < 50 pmol/L